All In Biotech

Drug Trial Radar · NCT03182504

A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants

A Non-Randomized, Open Label, One Treatment, One Group Study to Investigate the Intrapulmonary Lung Penetration of RO7079901 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Apr 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Jun 15, 2017

Primary completion

Aug 10, 2017

Study completion Aug 10, 2017

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the intrapulmonary penetration of nacubactam in healthy volunteers. Nacubactam is a novel non-beta-lactam beta-lactamase inhibitor being developed as a combination therapy with the beta-lactam meropenem for the treatment of serious gram-negative bacterial infections. Adult male and female healthy participants will receive a single intravenous infusion of nacubactam co-administered with meropenem and then undergo a bronchoalveolar lavage (BAL) procedure to collect lung epithelial lining fluid (ELF) for measurement of intrapulmonary concentrations of nacubactam and meropenem.

Conditions

  • Gram-negative Bacterial Infections

Interventions

  • nacubactamDrug

    Participants will receive a single 2000 milligram (mg) intravenous (IV) infusion of nacubactam over 1.5 hours.

  • meropenemDrug

    Participants will receive a single 2000 mg IV infusion of meropenem over 1.5 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Epithelial Lining Fluid (ELF) Concentration of Nacubactam to Plasma Concentration of Nacubactam RatioTime frame: At 2, 3, 4, 6 and 8 hours after study drug administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pulmonary Associates Clinical Trials (PACT)

    Phoenix, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.